CD274 and cancer: Subsequently, the current study turn attention to camrelizumab, a PD-1 immune checkpoint inhibitor, which blocks the binding site of PD-1 expressed on activated T lymphocytes, B cells, and natural killer cells to PD-L1 overexpressed on certain cancer cells.